Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) is reporting third quarter financial results on Thursday 29th October 2020, before market open.
According to analysts surveyed by Thomson Reuters, CNST is expected to report 3Q20 loss of $ 0.68 per share.
For the full year, analysts anticipate loss of $ 2.73 per share bottom line.
Stock Performance
Shares of Constellation Pharmaceuticals, Inc. traded up $ 0.57 or 2.50 percent on Wednesday, reaching $ 23.37 with volume of 480.10 thousand shares. Constellation Pharmaceuticals, Inc. has traded high as $ 23.45 and has cracked $ 21.83 on the downward trend
According to the previous trading day, closing price of $ 23.37, representing a 77.02 % increase from the 52 week low of $ 12.88 and a 61.67 % decrease over the 52 week high of $ 59.49.
The company has a market capital of $ 1.11 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Constellation Pharmaceuticals, Inc. will be hosting a conference call at 8:00 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.constellationpharma.com
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The companys lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors.
